Key Points:
TPM® Oxymorphone Patch pre-IND, FDA face-to-face meeting confirmed for December ‘18.
Injectable candidates continue to progress – development candidates on track for 2018 Tox
Multiple companies undertaking due diligence on Animal Health Business.
Strong Vital ET sales on forecast for 2018
Independent research coverage rates POH a ‘Buy’ with target 8-9 cents share price
Ann: Receipt of R&D Tax Incentive, page-16
Add POH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| POH (ASX) Chart |
Day chart unavailable
